Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191297 | 0.86 | MEN1 (0.45) | AKR1C3AKR1C2PTGS2ANTXR2ALDH1A1 | |
| SCHEMBL29349908 | 0.86 | MEN1 (0.45) | AKR1C3AKR1C2PTGS2ANTXR2ALDH1A1 | |
| SCHEMBL7070924 | 0.81 | AKR1C3 (0.33) | AKR1C3AKR1C2EGFRRETKDR | |
| Isocoumarin SCHEMBL745168 | 0.73 | AKR1B1 (0.42) | AKR1C3AKR1C2PTGS2ALDH1A1KDM4E | |
| SCHEMBL6840653 | 0.69 | EGFR (0.42) | EGFRRETKDRADORA3ANTXR2 | |
| SCHEMBL6348904 | 0.68 | EGFR (0.42) | AKR1C3AKR1C2EGFRRETKDR | |
| SCHEMBL29769302 | 0.67 | MEN1 (0.42) | PTGS2ANTXR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL6505805 | 0.67 | XDH (0.44) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL6945650 | 0.65 | MEN1 (0.48) | PTGS2ANTXR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL6352501 | 0.65 | RECQL (0.45) | AKR1C3AKR1C2PTGS2ANTXR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900239-B2 | Tumor chemopotentiation using isocoumarin derivatives | ILWZ ILEX PRODUCTS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-6589981-B2 | Combination treatment with ionizing radiation and/or chemotherapy | ILEX ONCOLOGY, INC. | 2003-07-08 | — | — | US | disclosed |
| US-20020165210-A1 | Tumor chemopotentiation using isocoumarin derivatives | GENZYME CORPORATION | 2002-11-07 | — | — | US | disclosed |
| US-20020019366-A1 | Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives | GLBC LLC | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019366-A1 | Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives | HCCS, IDH2, IDH3A | AKR1C3 3094/4885AKR1C2 2076/4885EGFR 3349/4885 |
| US-20020165210-A1 | Tumor chemopotentiation using isocoumarin derivatives | MCL1, IDH2, MYADM | AKR1C3 2208/4885AKR1C2 1151/4885EGFR 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.